Not rendering correctly? View this email as a web page here.

- April 2018 -


CLSI Hosts CARB-X Information and Networking Session

Read More


  • CLSI FAST Company Female Execs Defy Industry Norm | Read More
  • CSweetener: Mentoring for Women Healthcare Leaders | Read More
  • Inflammatix (FAST Fall 2017) is named a finalist in Fast Company’s 2018 World Changing Ideas Awards for its novel HostDx™ tests | Read More
  • Fatma Kaplan, CEO of Pheronym (FAST Fall 2017) talks about encountering high risk to get to the goal in sight | Read More
  • LogicInk (FAST Spring 2017) highlighted in the Proceedings of the National Academy of Sciences (PNAS): “Science and Culture: Wearable tech meets tattoo art in a bid to revolutionize both” | Read More
  • Eidos Therapeutics (FAST Spring 2016) announced completion of a $64.0 million Series B financing to advance Eidos’ small molecule product candidate, AG10 into Phase 2 clinical trials for the treatment of transthyretin (TTR) amyloidosis (ATTR) | Read More
  • Sandstone Diagnostics (FAST Fall 2013) deployed in a new NIH-funded research study to further evaluate the association between men’s semen parameters and fertility among couples trying to conceive | Read More
  • CLSA Fellows member twoXAR raised $10 million in a Series A financing led by SoftBank Ventures to build the company’s drug pipeline | Read More
  • ShangPharma Innovation expanded its incubator facility to provide science-driven entrepreneurs with affordable access to resources such as laboratory infrastructure and conferencing space | Read More

About FAST Advisory Program

The FAST Advisory Program provides select entrepreneurs with intensive team review and coaching to perfect their business model, product development plans, and to build a compelling commercialization strategy. Experienced entrepreneurs, product and business experts (which may include clinical development, regulatory, reimbursement and business development specialists) will advise selected Fellows during a twelve-week program, culminating in a Final FAST Showcase to a broad audience that includes potential investors and partners.

For information on the FAST program, contact Steve Karp at or Julie Harness at

Upcoming Events & Key Dates
4/15 DSM 2018 Health & Human Nutrition Innovation Conference, San Francisco, CA  Register Here
4/17 IndieBio Demo Day  Register Here
4/18 PwC Launch Training Session III: Launch Lessons for Commercialization Stage Webinar Register Here
4/19 Deadline to apply to be selected as a 2018 Rosenman Innovator  More Info
4/23 Stanford Drug Discovery Conference  Register Here
4/24 New Investors, Valuations and Recent Exits for Diagnostics Companies, UCSF Mission Bay  Register Here
5/1 Rosenman Institute D-Series: Investing Insights in Digital Health, UCSF Mission Bay  Register Here
5/9 JLabs Spotlight Science Fair at Stanford – Bringing it back to basics, Stanford, CA  Register Here
5/10 Meet with 5AM Ventures, JLabs, South San Francisco  Register Here
5/15 QB3 Seminar: Why do Diagnostic Companies Fail? UCSF Mission Bay  Register Here
5/17 JLabs and MilliporeSigma Discussion Panel: Navigating Technical and Regulatory Challenges with Confidence, South San Francisco  Register Here
5/22 World Class Innovation, World Class Path-to-Market, JLabs South San Francisco  Register Here
6/5 Meet with Pappas Capital, JLabs, South San Francisco  Register Here
6/20 5th Annual Rosenman Symposium, UCSF Mission Bay  Register Here



  • Read Op-Ed by Kevin Outterson, Executive Director of CARB-X, about innovative ways to pay for new antibiotics in STAT news. | Read More
  • CARB-X awards up to $2 million to HelixBind for the development of the company’s RaPID/BSI diagnostic test for invasive bloodstream infections | Read More
  • CARB-X awards up to $7.6 million to Shionogi to develop an antibiotic to treat infections caused by carbapenem-resistant Enterobacteriaceae (CRE) | Read More
  • CARB-X awards up to $1.7 million to Specific Diagnostics to support the development of a rapid accurate test to diagnose life-threatening drug-resistant infections in the blood | Read More
  • Powered by CARB-X company, Macrolide Therapeutics announced completion of a $20 million financing led by Advent Life Sciences, Gurnet Point Capital, Novartis Venture Fund, Roche Ventures and SR One and appointment of a new CEO | Read More
  • Powered by CARB-X company, T2 Biosystems, announced positive results from four studies of its T2Dx blood diagnostics system designed to detect pathogens that cause sepsis | Read More

Other AMR News

  • Genentech researchers have identified an antibody that spotlights a new target for antibiotic resistant bacteria, potentially paving the way for a new class of antibiotics | Read More
  • Researchers at Brown University may have discovered a new class of antibiotics chemically related to vitamin A that shows early promise by killing MRSA in mice | Read More
  • Arsanis, a clinical-stage biopharmaceutical company developing monoclonal antibodies for targeted immunotherapy of serious infections, announced an out-license agreement with BB100 for their preclinical stage E.coli monoclonal antibodies | Read More
  • Deinove, a France-based biotechnology company expanded its innovative antibiotic portfolio by signing a license option agreement with RedX Pharma for its first-in-class NBTI anti-infective program targeting resistant Gram-negative bacteria | Read More
  • Using high resolution microscopy, scientists have developed a new perspective on the bacterial cell wall Read More. Another group of scientists have discovered a structural weak spot in the cell wall, which may be a targetable spot for new antibacterial drugs Read More.

 About CARB-X

CARB-X is one of the world's largest public-private partnership devoted to early stage antibacterial R&D. Funded by ASPR/BARDA and Wellcome Trust, with in-kind support from NIAID, CARB-X is investing up to $455 million from 2016-2021 to support innovative products from ‘hit-to-lead’ phase through to Phase 1 clinical trials. CARB-X focuses on high priority drug-resistant bacteria, especially Gram-negatives. CARB-X operates through Boston University. Other partners include RTI International, the Broad Institute of Harvard and MIT, MassBio, and the California Life Sciences Institute (CLSI).

Upcoming Events
4/16 Duke-Margolis - Evaluating Inclusion and Exclusion Criteria in Clinical Trials, Washington D.C.  Register Here
4/21 28th European Congress of Clinical Microbiology and Infectious Diseases, Madrid, Spain Register Here
5/1 Deadline to submit cases on diagnostics and AMR to be used in medical education and shared online  More Info
5/3 CLSI CARB-X Information Session & Networking Event, San Diego Register Here
5/28 Countering Antimicrobial Resistance, Beijing, China  Register Here
6/7 ASM Microbe, Atlanta  Register Here
6/14 Duke-Margolis – important public meeting focused on Understanding the Development Challenges Associated with Emerging Non-Traditional Antibiotics  More Info
7/22 Gordon Research Conference on Drug Resistance for Cancer, Infectious Disease and Agriculture, Smithfield, RI  Register Here
9/20 ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, Lisbon, Portugal  Register Here


 STEM Education & Careers 

  • Guest Article: ARCS Symposium Meet the Minds of the Future | Read More
  • New MBA program caters to life science professionals in South San Francisco | Read More
  • Biotech Primer Article: Alzheimer’s Disease: A Tough Nut to Crack | Read More
  • Biotech Primer Article: Exploring Different Strategies to Fight Alzheimer’s | Read More
  • Biotech Primer Article: Cancer Diagnostic in a Drop | Read More
  • Biotech Primer Article: Turning on Cellular Garbage Disposals | Read More

About CLSI Education & Career Programs

CLSI helps build the next generation of life science professionals by bringing industry and institutions of learning together to improve STEM education in California and to inspire and develop life science careers. CLSI also works to ensure that the current and anticipated talent needs of the industry are met, and that the workforce pipeline for the industry remains strong.

Upcoming Events
4/14 March for Science Bay Area  Register Here
4/16 Biotech Bay Talent Connect  Register Here
4/18 SFSU MBA Information Session Lunch & Learn for Biotech Professionals  More Info
5/7 2018 ARCS Symposium Meet the Minds of the Future  More Info
5/16 SFSU MBA Information Session Lunch & Learn for Biotech Professionals  More Info



California Life Sciences Institute (CLSI) supports the foundations of innovation that have made California home to the world’s most prominent life sciences ecosystem. Our mission is to maintain California’s leadership in life sciences innovation through support of entrepreneurship, education and career development. CLSI also serves as an accelerator for CARB-X, the world’s largest public-private partnership devoted to early stage antibacterial R&D.

CLSI is an affiliate of the California Life Sciences Association (CLSA), which represents California’s leading life sciences organizations. The California Life Sciences Institute is a non-profit 501(c)(3), and was established in 1990 as the BayBio Institute.